Citations

Clear

3501 citation(s) found for "Xu, Timothy".

Competency-Based Time-Variable Anesthesiology Residency Training: Identification of Problems and Solutions
Fuller, Skylar L., Diachun, Carol Ann B., Kearney, Matthew D. , Long, Timothy R. , Juve, Amy K. Miller , Mitchell, John D., Woodworth, Glenn E. , Mitchell, Sally A. , Ambardekar, Aditee P. , Mitchell, John D.

Mayo Clinic

Anesthesia & Analgesia | July 14, 2023 | Volume: 138 | Issue: 4 | Pages: 848-855

10.1213/ane.0000000000006625 | PMID 37450642 Get It

BACKGROUND: Global medical education is gradually moving toward more comprehensive implementations of a competency-based education (CBE) model. Elimination of standard time-based training and adoption of time-variable training (competency-based time-variable training [CB-TVT]) is one of the final stages of implementation of CBE. While CB-TVT has been implemented in some programs outside the United States, residency programs in the United States are still exploring this approach to training. The Accreditation Council for Graduate Medical Education (ACGME) and the American Board of Medical Specialties (ABMS) are encouraging member boards and residency review committees to consider innovative ways programs could implement CB-TVT. The goals of this study were to (1) identify potential problems with the implementation of CB-TVT in anesthesiology residency training, (2) rank the importance of the problems and the perceived difficulty of solving them, and (3) develop proposed solutions to the identified problems. METHODS: Study participants were recruited from key stakeholder groups in anesthesiology education, including current or former program directors, department chairs, residents, fellows, American Board of Anesthesiology (ABA) board members, ACGME residency review committee members or ACGME leaders, designated institutional officials, residency program coordinators, clinical operations directors, and leaders of large anesthesiology community practice groups. This study was conducted in 2 phases. In phase 1, survey questionnaires were iteratively distributed to participants to identify problems with the implementation of CB-TVT. Participants were also asked to rank the perceived importance and difficulty of each problem and to identify relevant stakeholder groups that would be responsible for solving each problem. In phase 2, surveys focused on identifying potential solutions for problems identified in phase 1. RESULTS: A total of 36 stakeholders identified 39 potential problems, grouped into 7 major categories, with the implementation of CB-TVT in anesthesiology residency training. Of the 39 problems, 19 (48.7%) were marked as important or very important on a 5-point scale and 12 of 19 (63.2%) of the important problems were marked as difficult or very difficult to solve on a 5-point scale. Stakeholders proposed 165 total solutions to the identified problems. CONCLUSIONS: CB-TVT is a promising educational model for anesthesiology residency, which potentially results in learner flexibility, individualization of curricula, and utilization of competencies to determine learner advancement. Because of the potential problems with the implementation of CB-TVT, it is important for future pilot implementations of CB-TVT to document realized problems, efficacy of solutions, and effects on educational outcomes to justify the burden of implementing CB-TVT.
Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology
Chiorean, E. Gabriela , Chiaro, Marco Del , Tempero, Margaret A. , Malafa, Mokenge P. , Benson, Al B. , Cardin, Dana B. , Christensen, Jared A. , Czito, Brian G. , Dillhoff, Mary , Donahue, Timothy R. , Hardacre, Jeffrey M., Klute, Kelsey , Ko, Andrew H. , LoConte, Noelle K. , Lowy, Andrew M. , Masood, Ashiq , Moravek, Cassadie, Nakakura, Eric K. , Narang, Amol , Nardo, Lorenzo , Obando, Jorge, Reddy, Sushanth , Reyngold, Marsha , Scaife, Courtney L. , Shen, Jeanne , Truty, Mark J. , Vollmer, Charles M., Wolff, Robert A. , Wolpin, Brian M. , McCullough, Beth, Lubin, Senem, Darlow, Susan, Cardin, Dana B , LoConte, Noelle , Chung, Vincent , Dotan, Efrat , Fountzilas, Christos , Glazer, Evan S. , Hawkins, William G , Kunstman, John W. , Polanco, Patricio Marcelo

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 11, 2023 | Volume: 21 | Issue: 7 | Pages: 753-782

10.6004/jnccn.2023.0034 | PMID 37433437 Get It

Ampullary cancers refer to tumors originating from the ampulla of Vater (the ampulla, the intraduodenal portion of the bile duct, and the intraduodenal portion of the pancreatic duct), while periampullary cancers may arise from locations encompassing the head of the pancreas, distal bile duct, duodenum, or ampulla of Vater. Ampullary cancers are rare gastrointestinal malignancies, and prognosis varies greatly based on factors such as patient age, TNM classification, differentiation grade, and treatment modality received. Systemic therapy is used in all stages of ampullary cancer, including neoadjuvant therapy, adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Radiation therapy may be used in localized ampullary cancer, sometimes in combination with chemotherapy, but there is no high-level evidence to support its utility. Select tumors may be treated surgically. This article describes NCCN recommendations regarding management of ampullary adenocarcinoma.
Recipient and kidney graft outcomes of deceased donors with human immunodeficiency virus in the United States
Fontana, Lauren , El‐Rifai, Rasha , Bregman, Adam , Spong, Richard , Kirchner, Varvara A. , Kirchner, Varvara , Swanson, Kurtis J. , Pruett, Timothy L. , Jackson, Scott , Riad, Samy

Mayo Clinic

Transplant Infectious Disease | July 11, 2023 | Volume: 25 | Issue: 4 | Pages: No page available

10.1111/tid.14093 | PMID 37432941 Get It

AbstractBackgroundThe HIV Organ Policy Equity (HOPE) act afforded transplantation of organs from donors who have HIV. Herein we compared the long‐term outcomes of recipients with HIV by donor HIV testing status.MethodsUsing the Scientific Registry of Transplant Recipients, we identified all primary adult kidney transplant recipients who were HIV‐positive between 1/1/16‐12/31/21. Recipients were grouped into three cohorts according to the donor HIV status based on antibody (Ab) and nucleic acid testing (NAT): Donor Ab−/NAT− (n = 810), Donor Ab+ /NAT− (n = 98), and Donor Ab+/NAT+ (n = 90). We compared recipient and death‐censored graft survival (DCGS) by donor HIV testing status using Kaplan–Meier curves and Cox proportional hazards regression, censored at 3 years posttransplant. Secondary outcomes were delayed graft function (DGF) and the following 1‐year outcomes: acute rejection, re‐hospitalization, and serum creatinine.ResultsIn Kaplan–Meier analyses, patient survival and DCGS were similar by donor HIV status (log rank p = .667; log rank p = .388). DGF occurred more frequently in donors with HIV Ab−/NAT− testing compared with Ab+/NAT− or Ab+/NAT+ testing (38.0% vs. 28.6% vs. 26.7%, p = .028). Average dialysis time before transplant was twice as long for recipients who received organs from donors with Ab−/NAT− testing (p < .001). Acute rejection, re‐hospitalization and serum creatinine at 12 months did not differ between the groups.ConclusionsPatient and allograft survival for recipients living with HIV remains comparable irrespective of donor HIV testing status. Utilizing kidneys from deceased donors with HIV Ab+/NAT− or Ab+/NAT+ testing shortens dialysis time prior to transplant. image
Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Streck, Joanna M. , Lee, Ju‐Whei , Walter, Angela Wangari , Rosen, Rachel , Gareen, Ilana F. , Kircher, Sheetal Mehta , Herman, B. , Carlos, Ruth C. , Kumar, Shaji , Mayer, Ingrid A. , Fenske, Timothy S. , Neal, Joel W. , Hodi, F. Stephen , Kyriakopoulos, Christos E. , Tempany, Clare M. , Shanafelt, Tait D. , Mayer, IA , Rosen, Rachel L , Herman, Benjamin A , Saba, Nabil F , Fenske, Timothy S , Neal, Joel W , Atkins, Michael B. , Hodi, Frank Stephen , Kyriakopoulos, Christos E , Tempany, Clare , Shanafelt, Tait D , Wagner, Lynne , Land, Stephanie R , Park, Elyse R , Ostroff, Jamie S , Saba, Nabil F. , Wagner, Lynne I.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 6, 2023 | Volume: 32 | Issue: 11 | Pages: 1552-1557

10.1158/1055-9965.epi-23-0420 | PMID 37410096 Get It

Abstract Background: While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among patients with cancer in national trials. Methods: Cancer survivors (N = 756) enrolled in 9 ECOG-ACRIN clinical trials (2017–2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30 days. Results: Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30 days, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30 days. Males (vs. females; OR 4.33; P = 0 &lt; 0.01) and individuals not living with another person who smokes (vs. living with; OR, 8.07; P = 0 &lt; 0.01) were more likely to use ATPs only versus cigarettes only in the past 30 days. Conclusions: Among patients with cancer, cigarettes were the most prevalent tobacco product reported. Impact: Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.
American Radium Society Appropriate Use Criteria for the use of liver‐directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines
Hallemeier, Christopher L. , Sharma, Navesh , Anker, Christopher J. , Lee, Percy, Williams, Vonetta M. , Kennedy, Timothy J., Jethwa, Krishan R. , Kumar, Rachit , Russo, Suzanne , Jethwa, Krishan , Small, William , Hallemeier, Christopher Leigh , Selfridge, Jennifer Eva , Lee, Percy , Jabbour, Salma K , Liu, David M. , Kim, Ed, Tchelebi, Leila T. , Russo, Suzanne

Mayo Clinic

Cancer | July 6, 2023 | Volume: 129 | Issue: 20 | Pages: 3193-3212

10.1002/cncr.34931 | PMID 37409678 Get It

AbstractThe liver is a common site of cancer metastases. Systemic therapy is widely accepted as the standard treatment for liver metastases (LM), although select patients with liver oligometastases may be candidates for potentially curative liver resection. Recent data support the role of nonsurgical local therapies such as ablation, external beam radiotherapy, embolization, and hepatic artery infusion therapy for management of LM. Additionally, for patients with advanced, symptomatic LM, local therapies may provide palliative benefit. The American Radium Society gastrointestinal expert panel, including members representing radiation oncology, interventional radiology, surgical oncology, and medical oncology, performed a systemic review and developed Appropriate Use Criteria for the use of nonsurgical local therapies for LM. Preferred Reporting Items for Systematic reviews and Meta‐Analyses methodology was used. These studies were used to inform the expert panel, which then rated the appropriateness of various treatments in seven representative clinical scenarios through a well‐established consensus methodology (modified Delphi). A summary of recommendations is outlined to guide practitioners on the use of nonsurgical local therapies for patients with LM.
Mitochondrial MICOS complex genes, implicated in hypoplastic left heart syndrome, maintain cardiac contractility and actomyosin integrity
Birker, Katja , Ge, Shuchao , Theis, Jeanne L. , Marchant, James , Fogarty, Zachary C. , Missinato, Maria A , Kalvakuri, Sreehari , Grossfeld, Paul , Ocorr, Karen , Colas, Alexandre R. , Bodmer, Rolf , Theis, Jeanne L , Fogarty, Zachary C , Missinato, Maria A , Ocorr, Karen , Nelson, Timothy J , Colas, Alexandre R , Olson, Timothy M , Vogler, Georg , Bodmer, Rolf , Kirkland, Natalie J. , Engler, Adam Jeffrey , Nelson, Timothy J. , Olson, Timothy M. , Vogler, Georg

Mayo Clinic

eLife | July 5, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.83385 | PMID 37404133 Get It

Hypoplastic left heart syndrome (HLHS) is a severe congenital heart disease (CHD) with a likely oligogenic etiology, but our understanding of the genetic complexities and pathogenic mechanisms leading to HLHS is limited. We performed whole genome sequencing (WGS) on 183 HLHS patient-parent trios to identify candidate genes, which were functionally tested in the Drosophila heart model. Bioinformatic analysis of WGS data from an index family of a HLHS proband born to consanguineous parents prioritized 9 candidate genes with rare, predicted damaging homozygous variants. Of them, cardiac-specific knockdown (KD) of mitochondrial MICOS complex subunit dCHCHD3/6 resulted in drastically compromised heart contractility, diminished levels of sarcomeric actin and myosin, reduced cardiac ATP levels, and mitochondrial fission-fusion defects. These defects were similar to those inflicted by cardiac KD of ATP synthase subunits of the electron transport chain (ETC), consistent with the MICOS complex’s role in maintaining cristae morphology and ETC assembly. Five additional HLHS probands harbored rare, predicted damaging variants in CHCHD3 or CHCHD6 . Hypothesizing an oligogenic basis for HLHS, we tested 60 additional prioritized candidate genes from these patients for genetic interactions with CHCHD3/6 in sensitized fly hearts. Moderate KD of CHCHD3/6 in combination with Cdk12 (activator of RNA polymerase II), RNF149 ( goliath , E3 ubiquitin ligase), or SPTBN1 ( β-Spectrin, scaffolding protein) caused synergistic heart defects, suggesting the likely involvement of diverse pathways in HLHS. Further elucidation of novel candidate genes and genetic interactions of potentially disease-contributing pathways is expected to lead to a better understanding of HLHS and other CHDs.
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
Coveler, Andrew L. , Smith, David C. , Curti, Brendan D. , Goel, Sanjay , Kuzel, Timothy M. , Rixe, Olivier , Bajor, David L. , Gutierrez, Martin , Lee, Hun Ju , Heath, Elisabeth I. , Thompson, John A. , Ansari, Sahar , Jacquemont, Céline, Topletz‐Erickson, Ariel R. , Zhou, Peigen , Curti, Brendan , Goel, Sanjay , Phillips, Tycel , Mehta, Amitkumar , Markovic, Svetomir N. , Gajewski, Thomas Frank , Gopal, Ajay K. , Caimi, Paolo F. , Ansari, Sahar, Schmitt, Michael W. , Grilley‐Olson, Juneko E.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 29, 2023 | Volume: 11 | Issue: 6 | Pages: e005584

10.1136/jitc-2022-005584 | PMID 37385724 Get It

Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, possibly enabling greater immune stimulation than other CD40 agonists. A first-in-human phase 1 trial was conducted to examine safety, pharmacokinetics, and pharmacodynamics of SEA-CD40 monotherapy in patients with advanced solid tumors and lymphoma. Methods SEA-CD40 was administered intravenously to patients with solid tumors or lymphoma in 21-day cycles with standard 3+3 dose escalation at 0.6, 3, 10, 30, 45, and 60 µg/kg. An intensified dosing regimen was also studied. The primary objectives of the study were to evaluate the safety and tolerability and identify the maximum tolerated dose of SEA-CD40. Secondary objectives included evaluation of the pharmacokinetic parameters, antitherapeutic antibodies, pharmacodynamic effects and biomarker response, and antitumor activity. Results A total of 67 patients received SEA-CD40 including 56 patients with solid tumors and 11 patients with lymphoma. A manageable safety profile was observed, with predominant adverse events of infusion/hypersensitivity reactions (IHRs) reported in 73% of patients. IHRs were primarily ≤grade 2 with an incidence associated with infusion rate. To mitigate IHRs, a standardized infusion approach was implemented with routine premedication and a slowed infusion rate. SEA-CD40 infusion resulted in potent immune activation, illustrated by dose dependent cytokine induction with associated activation and trafficking of innate and adaptive immune cells. Results suggested that doses of 10–30 µg/kg may result in optimal immune activation. SEA-CD40 monotherapy exhibited evidence of antitumor activity, with a partial response in a patient with basal cell carcinoma and a complete response in a patient with follicular lymphoma. Conclusions SEA-CD40 was tolerable as monotherapy and induced potent dose dependent immune cell activation and trafficking consistent with immune activation. Evidence of monotherapy antitumor activity was observed in patients with solid tumors and lymphoma. Further evaluation of SEA-CD40 is warranted, potentially as a component of a combination regimen. Trial registration number NCT02376699.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
Sakemura, Reona , Hefazi, Mehrdad , Cox, Michelle J. , Siegler, Elizabeth L. , Sinha, Sutapa , Hansen, Michael J. , Stewart, Carli M. , Feigin, Jennifer M. , Roman, Claudia Manriquez , Schick, Kendall J. , Tapper, Erin E. , Horvei, Paulina , Fonkoua, Lionel Aurelien Kankeu , Ruff, Michael W. , Forsman, Cynthia L. , Nevala, Wendy K. , Boysen, Justin C. , Tschumper, Renee C. , Grand, Cory L. , Kuchimanchi, Kameswara R. , Mouritsen, Lars , Warner, Steven L. , Call, Timothy G. , Sakemura, R Leo , Manriquez Roman, Claudia , Can, Ismail , Tapper, Erin E , Horvei, Paulina , Adada, Mohamad M , Bezerra, Evandro D , Fonkoua, Lionel Aurelien A Kankeu , Ruff, Michael W , Forsman, Cynthia L , Nevala, Wendy K , Boysen, Justin C , Tschumper, Renee C , Grand, Cory L , Kuchimanchi, Kameswara R , Mouritsen, Lars , Foulks, Jason M , Warner, Steven L , Call, Timothy G , Parikh, Sameer A , Ding, Wei , Kay, Neil E , Kenderian, Saad Sirop , Hefazi, Mehrdad , Siegler, Elizabeth L , Cox, Michelle J , Sinha, Sutapa , Stewart, Carli , Can, İsmail , Bezerra, Evandro D. , Parikh, Sameer A. , Ding, Wei , Kay, Neil E. , Kenderian, Saad S.

Mayo Clinic

Cancer Immunology Research | June 28, 2023 | Volume: 11 | Issue: 9 | Pages: 1222-1236

10.1158/2326-6066.cir-22-0254 | PMID 37378662 Get It

Abstract The receptor tyrosine kinase AXL is a member of the TYRO3, AXL, and proto-oncogene tyrosine-protein kinase MER family and plays pleiotropic roles in cancer progression. AXL is expressed in immunosuppressive cells, which contributes to decreased efficacy of immunotherapy. Therefore, we hypothesized that AXL inhibition could serve as a strategy to overcome resistance to chimeric antigen receptor T (CAR T)–cell therapy. To test this, we determined the impact of AXL inhibition on CD19-targeted CAR T (CART19)–cell functions. Our results demonstrate that T cells and CAR T cells express high levels of AXL. Specifically, higher levels of AXL on activated Th2 CAR T cells and M2-polarized macrophages were observed. AXL inhibition with small molecules or via genetic disruption in T cells demonstrated selective inhibition of Th2 CAR T cells, reduction of Th2 cytokines, reversal of CAR T-cell inhibition, and promotion of CAR T-cell effector functions. AXL inhibition is a novel strategy to enhance CAR T-cell functions through two independent, but complementary, mechanisms: targeting Th2 cells and reversing myeloid-induced CAR T-cell inhibition through selective targeting of M2-polarized macrophages.